



PROJECT ECHO NL: OPIOID USE DISORDER

Session 7: Tuesday, March 2, 2021

Extended-Release Buprenorphine (Sublocade®): Indications and Use

Tuesday, March 2, 2021
8:30 – 9:30 am NST

Learning Objectives:

At the conclusion of this activity, participants will be able to:

- Discuss the indications and contraindications of using extended-release buprenorphine (Sublocade®) in the management of OUD.
- Explain the basic pharmacology of BPN in extended-release buprenorphine (Sublocade®), including its absorption, metabolism and elimination.
- Determine based upon the drug mechanics and patient profile who will be a suitable or unsuitable candidate for extended-release buprenorphine (Sublocade®) in their current practice.
- Explain the practical aspects of administration, including ordering, storage, administration, dose scheduling, dose discontinuation as well as proper documentation.
- Discuss the use of extended-release buprenorphine (Sublocade®) in special population groups and settings, such as pregnant women or incarcerated patients.

Speakers:

Dr. Ken Lee, MD MCFP (Addiction Medicine)

London RAAM Clinic,
CMHA Mental Health & Addictions Crisis Centre, and
Operational Stress Injury Clinic (St. Joseph's Health Care London)

Registration Information:

Sessions take place on Zoom.

To register for **Session 7**, please email Chelsea.Hynes@easternhealth.ca
by **Friday, February 26, 2021**.

Direct questions about Project ECHO NL: Opioid Use Disorder to:

Kate Lambert
Knowledge Exchange Facilitator
Provincial Opioid Dependence Treatment Centre of Excellence
Eastern Health
Kate.Lambert@easternhealth.ca

*This **Group Learning** program has been certified by the College of Family Physicians of Canada and the Newfoundland and Labrador Chapter for up to 10 Mainpro+ credits.*

Project ECHO NL: Opioid Use Disorder is funded through Health Canada's Substance Use and Addiction Program.



Advanced
Session